The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Correlation of Prostatic Nuclear Androgen Receptor Content with Duration of Response and Survival Following Hormonal Therapy in Advanced Prostatic Cancer
Abstract
To assess whether pre-treatment prostatic androgen receptor measurements would be of value in predicting the response to hormonal therapy in patients with prostatic cancer 23 men with metastatic carcinoma of the prostate underwent prostatic biopsy before treatment. Cytosolic and nuclear prostatic androgen receptor contents were measured by a single saturating dose, dextran-charcoal assay. All patients had measurable levels of androgen receptor in prostatic tissue and all demonstrated objective evidence of improvement following hormonal therapy. Thus, if androgen receptor measurements are to be useful in predicting prognosis correlations between quantitative levels of receptor and quantitative aspects of response must be established. In our study response was quantitated by measuring the duration of response and survival following hormonal treatment. The strong correlation between duration of response and survival (p less than 0.01) demonstrated herein suggests that survival in these patients is related directly to the duration of time patients respond to hormonal therapy. Neither total cellular nor cytosolic androgen receptor content correlated with response. However, nuclear androgen receptor content correlated with the duration of response and survival following hormonal treatment (p less than 0.05). Furthermore, in patients with nuclear receptor levels less than 110 fmol. per mg. deoxyribonucleic acid the duration of response (7.1 plus or minus 3.8 months) and survival (14.4 plus or minus 5.9 months) was significantly shorter than in patients with higher levels of nuclear receptor (17.3 plus or minus 10.4 and 24.7 plus or minus 8.8 months, respectively) (p less than 0.05). These findings, which are the first report of a correlation between nuclear androgen receptor content and hormonal responsiveness, suggest that measurements of nuclear receptor may aid in identifying those patients unlikely to obtain a prolonged response from hormonal therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Burton, K. (1956) · Biochemical Journal · doi:10.1042/bj0620315 · Cited by 14,090
Cited by
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Identification of androgen receptors in normal human osteoblast-like cells.
Colvard, D. S., Eriksen, E. F., Keeting, P. E., Wilson, E. M., Lubahn, D. B., French, F. S., Riggs, B. L., & Spelsberg, T. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.3.854 · Cited by 462
Androgen receptor gene mutations in human prostate cancer.
Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., Brown, T. R., & Barrack, E. R. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.14.6319 · Cited by 419
Metadata
- Authors
- Trachtenberg, J., & Walsh, P. C.
- Venue
- Journal of Urology
- Published
- 1982-03
- Volume
- 127
- Issue
- 3
- Pages
- 466-471
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2410021467
- Cited by
- 160
- References
- 1
- FWCI
- 24.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Correlation of Prostatic Nuclear Androgen Receptor Content with Duration of Response and Survival Following Hormonal Therapy in Advanced Prostatic Cancer. https://app.cochat.ai/papers/10.1016/s0022-5347(17)53868-9
- The paper
- Trachtenberg, J., & Walsh, P. C. (1982). Correlation of Prostatic Nuclear Androgen Receptor Content with Duration of Response and Survival Following Hormonal Therapy in Advanced Prostatic Cancer. Journal of Urology. https://doi.org/10.1016/s0022-5347(17)53868-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.